MBX Biosciences, Inc.
MBX$1.60B
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaCARMEL43 employees
Drugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
MBX News
Catalyst Timeline
0 upcoming, 1 past
No catalysts found.
Drug Pipeline
MBX 2109
Hypoparathyroidism
400 µg of MBX 2109 once-weekly by subcutaneous injection
Hypoparathyroidism
MBX 1416 (INN imapextide)
Postbariatric Hypoglycemia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
MBX 2109 | Phase 2 | Hypoparathyroidism | - | - |
400 µg of MBX 2109 once-weekly by subcutaneous injection | Phase 2 | Hypoparathyroidism | - | - |
MBX 1416 (INN imapextide) | Phase 2 | Postbariatric Hypoglycemia | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply